Looking on the Mahana Therapeutics website, it seems that originally the web version of Prof Moss-Morris's self management manual for CBT for IBS was called Regul8 but is now renamed Parallel on the Mahana Therapeutics website:
https://www.kcl.ac.uk/ioppn/depts/p...earchGroupings/healthpsych/research-group/IBS
"Irritable Bowel Syndrome Overview
Irritable Bowel Syndrome (IBS) affects 10–22% of the UK population. Current treatment relies on a positive diagnosis, reassurance, lifestyle advice and drug therapies, but many suffer on-going symptoms. Professor Moss-Morris has developed a CBT based self-management manual for treating IBS in primary care with minimal therapist contact. In collaboration with colleagues in Southampton, and funded through NIHR RfPB, a web version of this treatment approach was developed called Regul8. Publications from modelling work for the intervention and trials of the approaches are listed below "
Now called Parallel on the Mahana Therapeutics website :
https://www.mahanatx.com/treatments/parallel
"Parallel, formerly known as Regul8, originally was developed by Rona Moss-Morris Ph.D, Head of Psychology Department, King’s College London (KCL) in collaboration with Trudie Chalder, Ph.D, Professor of Cognitive Behavioural Psychotherapy and Alice Sibelli, Ph.D. at KCL and Dr. Hazel Everitt, Professor of Primary Care Research, University of Southampton. Initial clinical funding support was provided by the UK National Institute for Health Research (NIHR)"
..........................
And on that same link:
"The Parallel Approach
For years, CBT has been used
successfully to treat health issues like chronic pain (4) heart disease (5) and multiple sclerosis (6). Parallel takes CBT online to help reduce the severity of IBS.
Parallel Clinical Trial
The Parallel program was tested in the world’s largest (n=558) randomized, controlled trial of Cognitive Behavioral Therapy for IBS (the “ACTIB” Trial) 3.
The outcomes were dramatic and potentially game-changing for patients. Starting at just 3 months, patients experienced significant and clinically meaningful reduction in the severity of their IBS.
At 12 months 66% of patients reported significant and clinically meaningful reduction in the severity of their IBS .
On average, reduction in IBS severity was twice that of patients receiving medical care as usual.
3. Everett et al. Gut. 2019 Sep;68(9):1613-1623."
.....................
They are in the process of developing CBT treatments for IBD:
https://www.mahanatx.com/treatments/ibd-research
"A New Way to Treat IBD
Mahana is currently developing a personalized digital treatment for adolescents and adults with Inflammatory Bowel Disease. This product will be tested in a series of research studies and randomized, controlled trials. This treatment will tap into the power of Cognitive Behavioral Therapy (CBT) to help patients living with IBD."
..........................
https://www.mahanatx.com/publications
"Publications
A Decade of Peer-reviewed Research
Mahana is committed to developing safe and effective products. Below are links to peer-reviewed publications for Parallel1, our IBS treatment. Studies for our IBD treatment are in progress."